Legend Biotech Other Non-Current Liabilities 2019-2025 | LEGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Legend Biotech other non-current liabilities for 2024 were $0.006B, a 88.88% decline from 2023.
Legend Biotech other non-current liabilities for 2023 were $0.055B, a 601% increase from 2022.
Legend Biotech other non-current liabilities for 2022 were $0.008B, a 248.89% increase from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Legend Biotech other non-current liabilities for 2024 were $0.006B, a 88.88% decline from 2023.
Legend Biotech other non-current liabilities for 2023 were $0.055B, a 601% increase from 2022.
Legend Biotech other non-current liabilities for 2022 were $0.008B, a 248.89% increase from 2021.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.1B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$135.7B
Vertex Pharmaceuticals (VRTX)	$119.2B
Bristol Myers Squibb (BMY)	$94.5B
CSL (CSLLY)	$78.8B
GSK (GSK)	$77.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$40.6B
Argenex SE (ARGX)	$34B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$20.5B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.2B
Moderna (MRNA)	$12.2B
Exelixis (EXEL)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
Ascendis Pharma (ASND)	$10.7B
QIAGEN (QGEN)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.7B
Revolution Medicines (RVMD)	$7B